16 November 2026 · Updated November 2026 · 11 min read

Exosomes Explained for Patients: What They Are and Where They Appear in Aesthetic Appointments

What are exosomes in skincare? A plain-language patient guide: where they appear after microneedling, the FDA position, and what to ask your provider.

ExosomesExosomasPatient GuideExosome FacialMicroneedlingFDA RegulationSpanish
BB
Cited sources

Exosomes are tiny particles that cells release to carry proteins, fats and genetic messages to other cells. In aesthetic practices they appear as a material a provider spreads on the skin right after a procedure such as microneedling, and the FDA stated in 2019 that there are no FDA-approved exosome products.

This guide explains exosomes in plain words, in English and in Spanish, and shows where they appear during an appointment. It sets out what the FDA and the published studies say, and it ends with the questions worth asking a provider about source, lot documents, storage and labeling.

Where the FDA stands

The FDA stated in its 2019 public safety notification, and again in a 2024 consumer alert, that there are no FDA-approved exosome products. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners. Whether any appointment suits a given person is a decision for that person and their own licensed provider.

Understanding exosomes as tiny messages passed between cells

Cells release very small bubbles called extracellular vesicles, each wrapped in a thin fatty membrane. Van Niel, D’Angelo and Raposo described in a 2018 review how these vesicles let cells exchange proteins, lipids and genetic material, and they noted that much about where vesicles travel and what they do remains unknown.

Exosomes are one group within that family. Kalluri and LeBleu described them in a 2020 review in Science as particles averaging about 100 nanometers across, carrying nucleic acids, proteins, lipids and other molecules that reflect the cell that made them; a nanometer is one millionth of a millimeter.

Part of that cargo is RNA. Valadi and colleagues reported in 2007 that exosomes from mast cells carried messenger RNA and microRNA that could pass to other cells, a finding that drew wide attention to vesicle cargo, and microRNA content is now one of the features a careful supplier measures.

The International Society for Extracellular Vesicles advises in its MISEV2023 guideline that the general term extracellular vesicle be used when the exact origin of a particle has not been shown. That advice is why studies, product labels and this guide use the words exosome and vesicle side by side.

Reading the same terms in English and Spanish

Many patients in Miami and Puerto Rico read about these products in both languages. The table lines up the terms most often seen on clinic websites and product labels, with a plain meaning for each.

EnglishSpanishPlain meaning
ExosomesExosomasTiny vesicles released by cells, about 100 nanometers across (Kalluri 2020)
Extracellular vesicles (EVs)Vesículas extracelularesThe wider family that includes exosomes; the term MISEV2023 advises when origin is unproven
MicroneedlingMicroagujasA device makes very small channels in the outer layer of skin (FDA microneedling page)
RF microneedlingMicroagujas con radiofrecuenciaMicroneedling that also passes radiofrequency energy through the needles
TopicalTópicoApplied to the surface of the skin
Certificate of analysis (COA)Certificado de análisis (COA)The laboratory report for one production lot
Lot numberNúmero de loteThe code that ties a vial to its production record

So when someone asks what exosomes are in Spanish, the answer is exosomas, and a clinic page that says vesículas extracelulares is describing the same family of particles. The questions later in this guide work the same way in either language.

Exosomes appear in aesthetic appointments as a topical step after a procedure

Most published appointments follow the same order. The skin is cleansed, a device makes very small channels in the outer layer, and the exosome material goes on the surface right after, while those channels are still open.

Park GH and colleagues used microneedling as that procedure step in a 2023 randomized split-face study of 28 adults, with exosome solution on one side of the face and saline on the other over three sessions three weeks apart. Kwon and colleagues applied an exosome gel just after each fractional CO2 laser session in a 2020 double-blind split-face study of 25 adults, and Estupiñan, Ly and Goldberg applied exosome material after RF microneedling in a 2025 study of 15 adults.

StudyProcedure stepTopical stepParticipants and sessions
Park GH 2023MicroneedlingExosome solution on one side, saline on the other28 adults, 3 sessions
Kwon 2020Fractional CO2 laserExosome gel on one side, control gel on the other25 adults, 3 sessions
Estupiñan 2025RF microneedlingExosome material on one half, PRP on the other15 adults, 3 sessions
Abdel-Maguid 2021Fractional CO2 laserStem cell conditioned medium compared with laser alone33 adults, 3 sessions

The timing has a reason. Gupta and colleagues reported in 2011 that uncovered microneedle sites in human volunteers recovered their barrier within about two hours, and Hsieh and colleagues reported in 2026 that labeled vesicles passed through a skin tissue model only to a limited extent.

The FDA sets an important limit on the device side. Its microneedling page states that microneedling devices are not approved for delivering cosmetics, topical medications or other products into the skin, so the topical step is a choice the practice makes and should be able to explain.

Understanding the exosome facial from the patient’s chair

Clinics often call this appointment an exosome facial. The steps below follow the published studies and the FDA microneedling page, and each practice adapts them to its own device and product.

  • A first visit, where the provider reviews medicines, recent skin problems and past reactions; the FDA microneedling page lists situations in which the procedure may not be suitable.
  • Cleansing and standard photos, so changes can be compared over time, as the controlled studies above did.
  • The procedure step, such as microneedling, RF microneedling or a fractional laser, chosen and set by the provider.
  • The topical step, in which exosome material is spread over the surface while the channels are still open.
  • Aftercare instructions, including what to expect over the next week and whom to call with a question.

Most of the downtime comes from the procedure step, since the exosome material stays on the surface. The FDA lists dryness, redness, peeling, bruising and crusting among the common short-term effects of microneedling, and the Kwon 2020 participants recorded redness, swelling and dryness in a daily diary for a week after each laser session.

Understanding where exosome material comes from

Exosome products differ by the cells or plants they come from. The controlled studies above used material from adipose (fat tissue) stem cells, and Knauer and colleagues reported in a 2026 scoping review that human studies of topical exosomes used both human-derived and plant-derived sources.

Knauer and colleagues also surveyed 20 commercial products and reported that they carried minimal information on how the exosomes were isolated, how they were processed and how long they keep. That gap is why the source and the lot documents are the first things to ask about.

Understanding the FDA status of exosome products

The FDA stated in its 2019 public safety notification that there are currently no FDA-approved exosome products. The agency also stated that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, subject to premarket review and approval requirements.

The agency repeated that position in a 2024 consumer alert. That alert invites anyone with questions about how a regenerative medicine product is regulated to contact the FDA directly, and it asks patients and health care professionals to report problems through the MedWatch program.

ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners and makes no statement about outcome. The practitioner decides whether and how the material is used, and a patient can always ask the practice to explain that choice.

Understanding what the evidence does not yet show

The research on exosomes in aesthetic appointments is early, and the reviewers who rated it say so plainly. Gaebe and colleagues reviewed 16 studies with 503 participants in 2026 and reported that most found improvement in at least one skin measure with no serious adverse events reported, while rating the certainty of the evidence low or very low because of design limits, uneven measurement and short follow-up.

  • Small studies: the controlled studies in this guide enrolled between 15 and 33 people, so a few participants can shift the results.
  • Mixed comparisons: Abdel-Maguid and colleagues reported in 2021 no significant clinical difference between a fractional CO2 laser with stem cell conditioned medium and the laser alone, and Estupiñan and colleagues reported in 2025 that exosomes and PRP after RF microneedling performed equally.
  • Different products: a result reported for one product may not carry over to another made from different cells or by a different process, as the Knauer 2026 product survey makes clear.
  • Industry ties: the Kwon 2020 gels were supplied by their manufacturer, and Estupiñan 2025 was supported in part by a manufacturer grant.
  • Short follow-up: Wang, Bajwa and Rivers reported in a 2026 scoping review that small samples, short follow-up and single-arm designs limit the field.

Each of those limits points to a clear next step, and larger, better documented studies are being registered and published. Until they arrive, the most useful thing a patient can do is ask good questions.

Questions to ask your provider before an appointment

Good practices welcome these questions. Each one follows from a study or an FDA page cited in this guide.

  • Source: which exosome product will you use, who makes it, and what cells or plants does it come from?
  • Lot documents: what is the lot number of the vial for my session, and can the practice request that lot’s certificate of analysis from its supplier?
  • Storage: how was the product shipped and stored, and how soon after thawing is it applied? Görgens and colleagues reported in 2022 that storage buffer and temperature changed how well vesicles held up over time.
  • Labeling: what does the product label say about intended use, and is it labeled for topical use?
  • Device: which device will make the channels, is it FDA-authorized, and will a new needle cartridge be opened for my session, as the FDA suggests patients ask?
  • Training: what training and experience do you have with this device? The FDA microneedling page lists this question for patients.
  • Fees: what does the quoted fee cover, including the procedure step, the topical step and any follow-up visits?
  • Aftercare: what should I expect over the next week, whom do I call with a concern, and how would a problem be reported to the FDA through MedWatch?

If you do not yet have a provider, the practitioner finder on this site takes your state and city and looks for an independent licensed practitioner near you. ExaVeyra charges nothing for that introduction, and any fee for care is set by the practice you choose.

Understanding how ExaVeyra documents the material it supplies

A practice can answer the lot questions above from its supplier’s records. ExaVeyra exosome material ships frozen from the manufacturing facility on dry ice in every available format, and each lot carries its lot number.

A certificate of analysis is generated for every lot and is available on request, together with the characterization panel and the cold-chain records. Every ExaVeyra certificate of analysis reports serological testing for pathogens, and ExaVeyra shares microRNA characterization data with qualifying practices on request, so a provider can give a clear answer when a patient asks where the material came from and how it was handled.

MISEV2023 sets out how vesicle material should be characterized by size, concentration, marker proteins and appearance under a microscope. A certificate of analysis that follows those headings lets a provider compare a lot with the material described in a published study.

Looking ahead with better studies and clearer records

Exosomes are a young part of aesthetic practice with a fast-growing body of research, and each new study adds clearer detail about sources, appointments and product quality. Patients who ask good questions and practices that keep careful records both help the field move forward.

ExaVeyra supplies exosome material to licensed practitioners with the lot documents that make those conversations easy, and practices that want to carry it can apply for a verified account. Product and device names mentioned in this guide or its references are trademarks of their respective owners.

Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

References

  1. 1.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized, split-face trial over 12 weeks; three whole-face fractional CO2 laser sessions with exosome gel on one side and control gel on the other; adults (Korea); n = 25. Carries in this article: an exosome gel applied right after a laser session, and the authors’ report of milder redness and shorter downtime on the exosome side. Disclosure: the exosome and control gels were manufactured and supplied by ExoCoBio Inc., the exosome manufacturer; the authors declared no conflicts of interest.
  2. 2.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study; three microneedling sessions three weeks apart with exosome solution on one side and saline on the other, follow-up 6 weeks after the last session; adults (Korea); n = 28. Carries in this article: the clearest published model of a topical exosome step after microneedling, with the authors’ report of higher appearance scores on the exosome side and no serious adverse events observed. Disclosure: the PubMed record lists government research grants and no COI statement.
  3. 3.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, split-face, non-inferiority trial; three RF microneedling sessions with topical exosomes on one half of the face and PRP on the other; adults (USA); n = 15. Carries in this article: an exosome step after RF microneedling, and the authors’ report that both halves improved equally. Disclosure: supported in part by a research grant to the investigators’ practice from Benev Company Inc., an exosome product maker (full text); the authors declared no conflicts of interest.
  4. 4.Abdel-Maguid EM, Awad SM, Hassan YS, El-Mokhtar MA, El-Deek HE, Mekkawy MM. Efficacy of stem cell-conditioned medium vs. platelet-rich plasma as an adjuvant to ablative fractional CO2 laser resurfacing for atrophic post-acne scars: a split-face clinical trial. J Dermatolog Treat. 2021;32(2):242-249. PMID 31180258. doi:10.1080/09546634.2019.1630701Randomized split-face clinical trial in two groups with biopsies, three monthly sessions and a final assessment 3 months later; adults (Egypt); n = 33. Carries in this article: a null comparison, in which the authors reported no significant clinical difference between laser with topical stem cell conditioned medium and laser alone (p = .63). Disclosure: no COI statement in the PubMed record; academic authors.
  5. 5.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias and GRADE assessment, searches to June 2025; 16 studies, 503 participants. Carries in this article: most studies reported improvement in at least one skin measure and no serious adverse events were reported, while risk of bias was moderate to critical and certainty was low or very low. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
  6. 6.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026. Published online ahead of print. PMID 42411735. doi:10.1093/asj/sjag141Scoping review with a librarian-reviewed search (2394 records screened) plus a survey of 20 commercial products; 18 human studies, with human-derived and plant-derived sources. Carries in this article: the products surveyed carried minimal information on isolation, processing or shelf life, and human studies remain scarce. Disclosure: academic authors (USA); no COI statement in the PubMed record.
  7. 7.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610Scoping review (PRISMA-ScR) including US and EU trial registries; 17 human studies from 2020 to 2025. Carries in this article: the authors’ statement that small samples, short follow-up, single-arm designs and potential conflicts of interest limit the field. Disclosure: no COI statement in the PubMed record.
  8. 8.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 7 October 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products subject to premarket review and approval requirements.
  9. 9.U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. Content current as of 04/09/2024; verified 7 October 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomesAgency consumer alert (CBER). Carries in this article: the FDA restates that there are currently no FDA-approved exosome products, invites consumers with questions about how a regenerative medicine product is regulated to contact the agency, and points to MedWatch for reporting problems.
  10. 10.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 7 October 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devicesAgency device information page (CDRH). Carries in this article: the statement that microneedling devices are not approved for delivering cosmetics, topical medications or other products into the skin, and the questions the FDA suggests patients ask about provider training, device cleaning and a new needle cartridge for each session.
  11. 11.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled with task forces and more than 1,000 researchers. Carries in this article: the advice to use the general term extracellular vesicle when a particle’s origin has not been shown, and the characterization headings a certificate of analysis can follow. Disclosure: many consortium authors list EV company affiliations, declared in the article.
  12. 12.Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. PMID 32029601. PMC7717626. doi:10.1126/science.aau6977Narrative review in Science. Carries in this article: the plain description of exosomes as a subset of extracellular vesicles averaging about 100 nanometers across, carrying nucleic acids, proteins, lipids and metabolites that reflect the cell of origin. Disclosure: the authors declared patents licensed to, equity in, and consulting for Codiak Biosciences, an exosome company.
  13. 13.van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213-228. PMID 29339798. doi:10.1038/nrm.2017.125Narrative review in Nature Reviews Molecular Cell Biology. Carries in this article: extracellular vesicles as a way for cells to exchange proteins, lipids and genetic material, and the authors’ note that much about vesicle origin, targeting and fate remains unknown. Disclosure: academic authors (France); no COI statement in the PubMed record.
  14. 14.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study using electrical impedance across microneedle designs, with and without covering the skin. Carries in this article: uncovered microneedle sites recovered their barrier within about 2 hours, the reason published appointments apply topical material right after the procedure step. Disclosure: academic authors (Georgia Institute of Technology); no COI statement in the PubMed record.
  15. 15.Hsieh MW, Su YS, Chen LY, Zhang ZX, Su LJ, Lin HH, et al. Novel Approach for Assessment of Dermal Absorption of Extracellular Vesicle Products Using Immunoaffinity Fluorescent Nanodiamonds. Skin Pharmacol Physiol. 2026;39(1):35-46. PMID 41587148. doi:10.1159/000550612Laboratory permeation study with nanodiamond-labeled small vesicles (62.5 to 141.1 nm) on a skin tissue model. Carries in this article: passage of vesicles through the skin model was limited, which is why the published appointments pair the topical step with a procedure step. Disclosure: several authors are affiliated with developers of the nanodiamond label.
  16. 16.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238Laboratory stability study over up to 2 years across storage buffers and temperatures. Carries in this article: vesicles stored in plain phosphate-buffered saline lost recovery within days, while a buffer with human albumin and trehalose held vesicles at minus 80 degrees and through freeze-thaw cycles, the reason storage questions belong on the list. Disclosure: several authors list affiliation with Evox Therapeutics, an EV company.
  17. 17.Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-9. PMID 17486113. doi:10.1038/ncb1596Laboratory study with mouse and human mast cell lines, cited as an older landmark in addition to the recent sources. Carries in this article: the report that exosomes carry messenger RNA and microRNA that can be passed to other cells, the background to sequencing the microRNA cargo of each lot. Disclosure: academic authors (Sweden); no COI statement in the PubMed record.

Ask your practitioner how their exosomes are tested

Lab analysis shows what is in a lot: particle counts, vesicle markers, sterility and how the material was stored. A practice that sources carefully can answer these questions from its supplier’s records.

Frequently Asked Questions

What are exosomes in skincare?
Exosomes are tiny vesicles, about 100 nanometers across, that cells release to carry proteins, lipids and RNA, as Kalluri and LeBleu described in a 2020 review. In skincare appointments a provider applies exosome material to the skin surface, usually right after microneedling or a laser, as in the Park GH 2023 and Kwon 2020 studies. The FDA stated in 2019 that there are no FDA-approved exosome products.
What is "exosomes" in Spanish?
The Spanish word is exosomas, and clinic pages may also say vesículas extracelulares, the wider family of particles that includes exosomes. The MISEV2023 guideline from the International Society for Extracellular Vesicles advises the general term extracellular vesicle when the exact origin of a particle has not been shown.
What happens during an exosome facial?
The skin is cleansed, a procedure such as microneedling, RF microneedling or a fractional laser makes very small channels, and exosome material is spread on the surface right after. Park GH and colleagues described this sequence with microneedling in 2023 and Kwon and colleagues with a fractional CO2 laser in 2020. Gupta and colleagues reported in 2011 that uncovered microneedle channels close within about two hours.
How are exosomes used in an aesthetic appointment?
In the published studies, exosome material is used as a topical step after a procedure. Estupiñan, Ly and Goldberg applied it after RF microneedling in 2025, and Park GH and colleagues applied it after microneedling in 2023. The FDA microneedling page states that microneedling devices are not approved for delivering topical products into the skin, so the provider decides and explains that step.
How much do exosomes cost at a clinic?
Each practice sets its own fee, and ExaVeyra does not publish patient prices. The fee usually reflects the procedure step, the product and the number of visits; the published studies scheduled three sessions, as in Park GH 2023 and Kwon 2020. Knauer and colleagues reported in 2026 that commercial products vary widely in source and documentation, so asking which product the fee covers is worthwhile.
Are exosomes FDA-approved?
No. The FDA stated in its 2019 public safety notification, and again in a 2024 consumer alert, that there are currently no FDA-approved exosome products. The agency asks patients and health care professionals to report problems with these products through its MedWatch program.
What should I ask my provider about exosomes?
Ask which product will be used and what cells or plants it comes from, the lot number of the vial and whether the lot’s certificate of analysis can be requested from the supplier, how the product was shipped and stored, and what its label says about topical use. Görgens and colleagues reported in 2022 that storage conditions changed how well vesicles held up, and the FDA microneedling page suggests asking about training and a new needle cartridge for each session.
How strong is the evidence on exosomes in aesthetic appointments?
Early. Gaebe and colleagues reviewed 16 studies with 503 participants in 2026 and reported that most found improvement in at least one skin measure with no serious adverse events reported, while rating the certainty of the evidence low or very low. Abdel-Maguid and colleagues reported in 2021 no significant clinical difference between a laser with stem cell conditioned medium and the laser alone.

ExaBlog Weekly for licensed practices

One email a week for licensed practices: new ExaBlog research reviews, practice guides and regulatory updates, each article citing its sources.

We write in English unless you check this box.

No spam. Unsubscribe any time.